Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

Twenty-six percent of heart attack survivors are confused about the role aspirin plays in secondary MI prevention, according to a recent survey from Bayer—a phenomenon that can be attributed in large part to an onslaught of conflicting headlines in the news this summer.

Annual hospital PCI-related mortality rates might be unreliable measures of a center’s performance, according to work published in JAMA Cardiology, proving unhelpful for identifying high-quality care in a study of 67 New York hospitals.

A 90-minute communication skills course improved conversations about ICD deactivation and goals of care between clinicians and their patients, according to the recently published results of the WISDOM study.

An analysis of the long-running Framingham Heart Study has revealed that exposure to secondhand smoke in childhood increases a person’s lifetime risk of atrial fibrillation.

Torrent Pharmaceuticals Limited is the latest drug company to issue a recall of losartan potassium, a popular blood pressure drug that’s been under scrutiny for more than a year for containing probable human carcinogens.

A therapeutic shoe designed to improve stroke survivors’ gait and symmetry was successful in a small-scale trial of six patients, according to a study published in the Journal of NeuroEngineering and Rehabilitation.

Research presented at the American Heart Association’s Hypertension 2019 Scientific Sessions this month suggests having high blood pressure speeds up cognitive decline in middle-aged and older adults—but treating the condition can reverse that possibility.